Belgium Diabetes Therapeutics Market Analysis

Belgium Diabetes Therapeutics Market Analysis


$ 3999

Belgium's diabetes therapeutics market is expected to grow from $317 Mn in 2022 to $664 Mn in 2030 with a CAGR of 9.7% for the forecasted year 2022-30. The increasing demand for novel treatment options for diabetes and supportive government policies for preventing diabetes in Belgium are the major market drivers. The Belgium diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Fagron Belgium, Dafra Pharma, and AstraZeneca are the major players in the Belgium diabetes therapeutics market.

ID: IN10BEPH036 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Dr. Parul Choudhary

Buy Now

Belgium Diabetes Therapeutics Market Executive Analysis

Belgium's diabetes therapeutics market is expected to grow from $317 Mn in 2022 to $664 Mn in 2030 with a CAGR of 9.7% for the forecasted year 2022-30. Belgium is placed ninth overall in the World Index of Healthcare Innovation with a score of 51.99. Belgium finished tenth in 2021 and 2022. Belgium has outperformed other countries in science and technology. With the second-highest R&D spending per capita among Index countries, China ranks eighth overall. Belgium is ranked tenth for budgetary sustainability. Belgium ranks third lowest in the Index regarding public healthcare spending, but its budgetary trend is off course. Belgium, which ranks 22nd on the Index, drops into the lowest third as public healthcare spending increases. An alarmingly high debt-to-GDP ratio and Belgium's even lower (number 23) national solvency score make the country's rising public healthcare spending a cause for concern.

6.6% of Belgians had been diagnosed with diabetes as of 2020. The estimated actual prevalence of diabetes is placed at 10% since more than one in three diabetics are unaware of their condition. As the population ages and the chance of having diabetes rises, there is a growing prevalence of diabetes. Compared to the Flemish region, the prevalence of diabetes is higher in the Walloon and Brussels Capital regions. People with lower socioeconomic status also have greater prevalence rates. These socioeconomic variations in diabetes incidence are particularly evident in the prevalence of undiagnosed or inadequately managed diabetes.

The incretin hormone glucagon-like peptide (GLP-1) has various anti-diabetic properties, including stimulation of glucose-dependent insulin secretion, elevation of insulin gene expression, and improvement in beta-cell survival. The detailed evaluation of the therapeutic efficacy of GLP-1 in animal models of type 2 diabetes (T2DM) has been made possible thanks to the recent exploitation of various routes of gene delivery and alternative means of gene transfer. Despite the initial technical challenges and profound inefficiency of direct gene transfer into the pancreas, which severely restricted in vivo gene transfer experiments with GLP-1. Numerous clinical advantages of GLP-1 peptide/analogues, including the development of glucose tolerance, the decrease of hyperglycemia, the suppression of appetite, and the relationship between food intake and weight loss, have been duplicated in animal models employing gene therapy as a result. Additionally, GLP-1-centered gene therapy not only increased insulin sensitivity but also significantly changed the adipokine profiles of treated individuals, reducing abdominal and/or hepatic fat linked to obesity-induced T2DM.

Belgium Diabetes Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Diabetes and its effects are becoming more widely known in Belgium's general population. The need for diabetes medicines and preventative strategies is rising as a result of this. Therapeutics for diabetes have advanced significantly, including the creation of novel medications and delivery methods. The Belgium diabetes therapeutics market is expanding because these developments are making it simpler and more convenient for patients to manage their diabetes. The Belgian government has launched a number of initiatives to support diabetes prevention and management. For instance, the government has enacted legislation to increase access to diabetes care and has started a number of efforts to increase diabetes awareness.

Market Restraints

Diabetes treatments can be costly, which can be a major obstacle for people without access to good health insurance. This may reduce the market's ability to expand. The availability of generic medications is expanding in the Belgian market for diabetic treatments, which is placing pressure on the cost of name-brand medications. As a result, pharmaceutical firms may be forced to make smaller investments in R&D as a result of decreased income. The Belgium diabetes therapeutics market is becoming increasingly competitive, which is forcing businesses to create more efficient and cost-effective products. Reduced market investment and profitability may result from this.

Competitive Landscape

Key Players

  • Indigo Diabetes (BEL)- The company Indigo Diabetes N.V. (Indigo) is a pioneer in the development of nanophotonic-based medical solutions. The world's first invisible sensor is currently being developed by Indigo for diabetics in order to meet their requirement for ongoing, accurate glucose and ketone monitoring with a better user experience
  • Neogen (BEL)
  • Mirrhia (BEL)
  • Fagron Belgium (BEL)
  • Dafra Pharma (BEL)
  • Astrazeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • Glaxosmithkline
  • Johnson Johnson
  • Merck
  • Novo Nordisk

Notable Deals

September 2022- The SHINE clinical trial, which is intended to assess the longer-term stability of Indigo's continuous multi-metabolite (or "CMM") device, has enrolled its first participant in Belgium. Indigo Diabetes N.V., a pioneer in developing medical solutions using nanophotonics, made the announcement today. For the continuous measurement of glucose, ketone, and lactate levels in diabetics, Indigo is developing a subcutaneously placed CMM device. The first of 15 people to be enrolled in the trial spanning Belgium, France, and Slovenia has been enrolled, marking a key Company milestone, at Antwerp University Hospital (UZA).

Healthcare Policies and Regulatory Landscape

The official body responsible for issuing licenses for medicines and health products in Belgium is the Federal Agency for Medicines and Health Products (Agence Federerale des Medicaments et des Produits de Sante, FAMHP), which was formerly known as the Directorate-General for Medicinal Products of the FPS Public Health and established in January 2007. The agency's job is to guarantee the efficacy, safety, and quality of drugs and other medical supplies both during the clinical development process and once they reach the market. In accordance with the national, decentralized, and mutual recognition procedures outlined in the Royal Decree of December 12, 2006, it is also in charge of approving the first national marketing application for a pharmaceutical product. No medication may be marketed in Belgium without registration or marketing authorization. On the basis of the applicant's scientific data, the experts chosen by the various agencies assess the drug's quality, safety, and efficacy. They rely on European-level scientific criteria for this assessment. Only items with clear evidence of their quality, safety, and effectiveness are authorized for marketing as drugs. The same scientific requirements for quality, safety, and efficacy must be met by all medications approved for commercialization, whether they are brand-name or generic.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Therapeutics Segmentation

By Type (Revenue, USD Billion):

  • Diabetes 1
  • Diabetes 2

By Application (Revenue, USD Billion):

  • Preventive
    • Prediabetes
    • Nutrition
    • Obesity
    • Lifestyle Management
  •  Treatment/Care
    • Diabetes
    • Smoking Cessation
    • Musculoskeletal Disorders
    • Central Nervous System Disorders
    • Cardiovascular Disease
    • Medication Adherence
    • Chronic Respiratory Disorders
    • Gastrointestinal Disorders
    • Rehabilitation
    • Substance Use Disorders & Addiction Management

By Drug (Revenue, USD Billion):

  • Oral Anti-diabetic Drugs
  • Insulin
  • Non-insulin Injectable Drug
  • Combination Drug

By Route of Administration (Revenue, USD Billion):

  • Oral
  • Subcutaneous
  • Intravenous

By Distribution Channel (Revenue, USD Billion):

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Fagron Belgium, Dafra Pharma, and AstraZeneca are the major players in the Belgium diabetes therapeutics market.

The Belgium diabetes therapeutics market is expected to grow from $317 Mn in 2022 to $664 Mn in 2030 with a CAGR of 9.7% for the forecasted year 2022-2030.

The Belgium diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 27 September 2023
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up